irAEs such as colitis, hypophysitis, and rash were more frequently reported in clinical trials with CTLA-4 inhibitors, whereas pneumonitis, hypothyroidism, arthralgia, and vitiligo were more common with PD-1/PD-L1 inhibitors [57] though all of these complications are observed with each ICI class. Here, PDCD1 is linked to hypothyroidism.